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Abstract: There has been increasing recognition that the second-generation antipsychotic 
drugs can produce extrapyramidal side effects. This case reports the development of severe 
akathisia in a patient being treated with ziprasidone for bipolar depression. The case illustrates 
that this symptom can be easily mistaken for worsening agitated depression. Akathisia may 
produce considerable distress and elevate suicide risk. Such symptoms may persist for weeks 
and be refractory to discontinuation of the offending agent or to pharmacological interventions 
commonly used to mitigate this reaction.
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Introduction
The efficacy of psychotropic drugs is frequently limited by lack of adherence to their 
use. Adherence rates decline in direct proportion to side effects experienced. Lack of 
adherence to antipsychotic treatment regimens has been identified as an unmet need 
of many with severe mental illness.1 A reduced risk of extrapyramidal side effects is 
often cited as an advantage of second-generation antipsychotics over the “typicals.” 
Compliance with first-generation antipsychotic drugs is frequently limited by the 
appearance of dystonias, drug induced Parkinsonism, and akathisia.2,3
Recent observations have shown that atypical agents may also produce troubling 
extrapyramidal side effects.4 We report a case of akathisia persisting for weeks follow-
ing dosage increases of ziprasidone used to treat bipolar depression.
While there have been several reports of akathisia associated with onset of use or 
with tapering of ziprasidone, this is the first case known to the authors of persistence 
of akathisia for an extended period after discontinuation of the drug.5,6
This case illustrates the dilemma of differentiating akathisia from psychomotor 
agitation. The case also demonstrates that akathisia can be quite refractory to common 
interventions such as discontinuation or addition of pharmacological interventions 
commonly used to treat this condition. Importantly, the case also shows how akathisia 
may persist for several weeks causing such distress that the symptom itself may lead 
to development of a sense of hopelessness, elevating suicide risk.7
Case report
A 67-year-old female was diagnosed with bipolar II disorder after presentation at age 64 
with symptoms of subjective depression, lethargy, anhedonia, insomnia with mid-cycle 
awakening, and irritability. By the patient’s self-report, she had suffered prior episodes 
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of hypomania occurring in spring and depression occurring 
frequently in early fall. She first sought treatment for depression 
at age 40 when she reported improvement with an unknown 
antidepressant drug. She discontinued this agent several months 
later and had not come again to psychiatric treatment until 
age 64. At the time of this presentation a Quick Inventory of 
Depression Symptoms (QIDS) score of 17 was noted. A trial of 
sertraline, increased over 6 weeks to 200 mg, resulted in mod-
erate improvement but with continued depressive symptoms, 
and a QIDS score of 9. After a switch in the antidepressant to 
venlafaxine at 150 mg she developed an episode of hyperac-
tivity, pressured speech, and grandiosity, for which she was 
hospitalized. Quetiapine at 300 mg per day resulted in return 
to a euthymic state. After experiencing daytime sedation with 
reduced dosage, quetiapine was discontinued. One year later 
she presented again for a routine office visit in mid-autumn, 
complaining of a sudden onset of depressive symptoms.
She had left her job from which she had previously gained 
a good deal of gratification, became socially withdrawn, and 
noted increased anxiety, diminished appetite, reduced levels 
of energy, and anhedonia. Three separate trials of lithium 
at 600 mg per day at different times over several months 
were terminated after she experienced increased subjective 
dysphoria. A trial of valproate resulted in subjective cognitive 
dulling and motor incoordination.
Ziprasidone was then begun and increased to 80 mg over 
the next 5 days. One week later the patient returned and 
reported that her depression, withdrawal, and anergy were 
unimproved (QIDS score 15) and that levels of anxiety had 
increased, causing considerable distress. Ziprasidone was 
increased from 80 mg to 120 mg over the next week and 
clonazapam 0.5 mg twice a day was begun, to address increas-
ing anxiety and agitation. Again, after 5 days, she reported 
that she felt restless and was unable to sit for long periods. 
Suffering increasing discomfort, she was brought to the 
emergency department with symptoms of agitation, anxiety, 
and hopelessness. She was admitted to the inpatient psychi-
atric program for treatment of worsening depression failing 
outpatient intervention. After admission, she described her 
symptoms as being unable to bear sitting down, a continuous 
feeling of anxiety, and pervasive insomnia. She also described 
a rather profound subjective despondency and developed pas-
sive suicidal ideation, expressing that she did not believe she 
could tolerate feeling as she did for very long. She was fre-
quently observed standing in one place and shuffling her feet. 
Akathisia was recognized at this time, and ziprasadone was 
discontinued. Amantadine 100 mg twice a day was begun, 
but the patient was unimproved 4 days later. Light therapy 
of 10,000 lux was started each early morning for 30 minutes 
predawn. Quetiapine 25 mg at night was added.
After 1 week, the symptom profile remained unchanged. 
Amantadine was discontinued and the patient was started on 
propranolol 10 mg three times a day, titrated up to 60 mg per 
day. Also, lorazepam 0.5 twice a day was begun. By day 5 of 
inpatient hospitalization, there was no improvement. Cogentin 
1 mg twice a day was added. One week later, with no improve-
ment in her movements or feelings of anxiety, propranolol was 
discontinued after the patient was noted to have symptoms 
and findings consistent with orthostatic hypotension. Car-
bidopa/levodopa was added after observation of continued 
shuffling gait, masked facies, and mild pill-rolling movement. 
Consultation with the hospital’s neurology department led to 
discontinuation of anti-Parkinson agents and confirmed the 
impression that akathisia was responsible for the majority of 
the patient’s distress. Nebivolol 5 mg was started and titrated 
to 10.5 mg once a day for several days without improvement. 
After 15 days of inpatient treatment there was little change. 
There were occasions of mild improvement of akathisia 
symptoms subjectively, but the distressing shuffling of her 
feet and inability to sit remained a constant. After discussion 
with family members and daily completion of structured sui-
cide assessments providing assurance of nonsuicidality, she 
was discharged to close outpatient follow-up with persistent 
symptoms of akathisia (QIDS score 12). After discharge, the 
patient’s akathisia resolved slowly over a period of 3 weeks 
and depressive symptoms were noted to improve.
Discussion
It is now established that akathisia may occur following use of 
second-generation or atypical antipsychotic agents, including 
clozapine.8,9 The incidence of these reactions appears to vary 
with the agent used, with risperidone producing more reports 
than ziprasidone.10 Rates of akathisia with ziprasidone are 
estimated to occur in 14% of patients at 80 mg and 13% at 
160 mg compared with a 7% rate for placebo in one series of 
patients with schizophrenia and schizoaffective disorder.11
Akathisia is characterized by a persistent sense of dis-
comfort remaining at rest accompanied by motor restlessness 
causing considerable distress. The presence of akathisia can 
be confused by patients and physicians with worsening of 
the underlying psychiatric disorder. Akathisia has been asso-
ciated with elevated risk of suicide.12 In a group of schizo-
phrenic patients, one study suggested that increased rates on 
the suicide subscale of the Hamilton Depression Inventory 
(HAMD) were double for those experiencing akathisia, com-
pared with those without this adverse reaction.13
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Second-generation antipsychotics have had expanding 
indications and are increasingly being recommended for use 
in the treatment of bipolar depression.14,15 Increased risk of 
akathisia with second-generation antipsychotic agents has 
been associated with their use in management of affective 
disorders.16
Conclusion
Clinicians should be aware of the potential for second-
generation antipsychotic drugs to produce akathisia, 
complicating treatment. This distressing symptom may 
persist for weeks and confound diagnostic assessment. 
Despite discontinuation, akathisia may be relatively 
refractory to standard interventions and confound evaluation 
of underlying mood disorder.
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